AlluriRVMohanVKomandurSChawdaKChaudhuriJRHasanQ. MTHFR C677T gene mutation as a risk factor for arterial stroke: a hospital based study. Eur J Neurol. 2005;12
(1):40–44.
VargaEASturmACMisitaCPMollS.Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation. 2005;111
(19):e289–e293.
4.
ChaiAUAbramsJ. Homocysteine: a new cardiac risk factor?Clin Cardiol. 2001;24
(1):80–84.
5.
DudmanNPGuoXWGordonRBDawsonPAWilckenDE. Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J Nutr. 1996;126(4 suppl):1295S–1300S.
6.
DurellJRawitscherMSturtevantJM. The synthesis of methionine by enzymic transmethylation. VIII. Enthalpy changes in the methyl-transfer from betaine and S-methylmethionine bromide. Biochim Biophys Acta. 1962;56:552–558.
7.
ZhangPGaoXZhangY. Association between MTHFR C677T polymorphism and venous thromboembolism risk in the Chinese population: a meta-analysis of 24 case-controlled studies [published online on August 21, 2014]. Angiology. 2014. doi:10.1177/0003319714546368
8.
ErogluAAkarN. Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and the risk of tamoxifen-associated thromboembolism in breast cancer patients. Thromb Res. 2011;127
(4):384–385.
9.
PatnaikMDlottJSFontaineRN. Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay. J Mol Diagn. 2004;6
(2):137–144.
10.
ZhouXQianWLiJ. Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis. Thromb Res. 2013;132
(5):531–536.
11.
GohilRPeckGSharmaP. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost. 2009;102
(2):360–370.
12.
FrederiksenJJuulKGrandeP. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen city heart study. Blood. 2004;104
(10):3046–3051.
13.
BonaaKHNjolstadIUelandPM. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354
(15):1578–1588.
14.
GhoshKShettySMadkaikarM. Venous thromboembolism in young patients from western India: a study. Clin Appl Thromb Hemost. 2001;7
(2):158–165.
15.
JangMJJeonYJChoiWI. The 677C > T mutation of the MTHFR gene increases the risk of venous thromboembolism in Koreans and a meta-analysis from Asian population. Clin Appl Thromb Hemost. 2013;19
(3):309–314.
16.
RayJGShmorgunDChanWS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb. 2002;32
(2):51–58.
17.
ZappacostaBMastroiacovoPPersichilliS. Homocysteine lowering by folate-rich diet or pharmacological supplementations in subjects with moderate hyperhomocysteinemia. Nutrients. 2013;5
(5):1531–1543.
18.
QinXLiJCuiY. MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults. Nutr J. 2012;11:2.
19.
CriderKSZhuJHHaoL. MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. Am J Clin Nutr. 2011;93
(6):1365–1372.
20.
BazzanoLA. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci. 2009;338
(1):48–49.
21.
AlbertCMCookNRGazianoJM. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299
(17):2027–2036.
22.
LonnEYusufSArnoldMJ. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354
(15):1567–1577.
23.
GalanPKesse-GuyotECzernichowS. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.
24.
YangQBaileyLClarkeR. Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults. Am J Clin Nutr. 2012;95
(5):1245–1253.
25.
MagerAOrvinKKoren-MoragN. Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease. Am J Cardiol. 2009;104
(6):745–749.
26.
WangYLiXQinX. Prevalence of hyperhomocysteinaemia and its major determinants in rural Chinese hypertensive patients aged 45-75 years. Br J Nutr. 2013;109
(7):1284–1293.
27.
WilsonCPWardMMcNultyH. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr. 2012;95
(3):766–772.
28.
WilsonCPMcNultyHWardM. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. 2013;61
(6):1302–1308.
29.
SwartKMEnnemanAWvan WijngaardenJP. Homocysteine and the methylenetetrahydrofolate reductase 677C-->T polymorphism in relation to muscle mass and strength, physical performance and postural sway. Eur J Clin Nutr. 2013;67
(7):743–748.
30.
NieminenTKnuutiJHamelahtiP. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vascul Pharmacol. 2007;47
(2-3):113–117.
31.
ArnadottirMHultbergBWahlbergJFellstromBDimenyE. Serum total homocysteine concentration before and after renal transplantation. Kidney Int. 1998;54
(4):1380–1384.
32.
NikolicDBanachMNikfarS. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?Int J Cardiol. 2013;168
(6):5437–5447.
33.
KasaharaMNakagawaTYokoiH. Do statins play a role in renoprotection?Clin Exp Nephrol. 2014;18
(2):282–285.
34.
DrewesYMPoortvlietRKBlomJW. Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk. J Am Geriatr Soc. 2014;62
(2):213–221.
35.
GiralPBruckertEJacobNChapmanMJFogliettiMJTurpinG. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis. 2001;154(2):421–427.
